CA2020752A1 - Traitement des affections des os - Google Patents

Traitement des affections des os

Info

Publication number
CA2020752A1
CA2020752A1 CA2020752A CA2020752A CA2020752A1 CA 2020752 A1 CA2020752 A1 CA 2020752A1 CA 2020752 A CA2020752 A CA 2020752A CA 2020752 A CA2020752 A CA 2020752A CA 2020752 A1 CA2020752 A1 CA 2020752A1
Authority
CA
Canada
Prior art keywords
amylin
bone
treatment
disorders
variants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2020752A
Other languages
English (en)
Other versions
CA2020752C (fr
Inventor
Iain Macintyre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
Original Assignee
Amylin Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Corp filed Critical Amylin Corp
Publication of CA2020752A1 publication Critical patent/CA2020752A1/fr
Application granted granted Critical
Publication of CA2020752C publication Critical patent/CA2020752C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA002020752A 1989-07-08 1990-07-09 Traitement des affections des os Expired - Lifetime CA2020752C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8915712.7 1989-07-08
GB898915712A GB8915712D0 (en) 1989-07-08 1989-07-08 Medical treatment

Publications (2)

Publication Number Publication Date
CA2020752A1 true CA2020752A1 (fr) 1992-01-10
CA2020752C CA2020752C (fr) 1996-12-24

Family

ID=10659773

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002020752A Expired - Lifetime CA2020752C (fr) 1989-07-08 1990-07-09 Traitement des affections des os

Country Status (12)

Country Link
EP (1) EP0408284B1 (fr)
JP (1) JPH04500691A (fr)
AT (1) ATE137975T1 (fr)
CA (1) CA2020752C (fr)
DE (1) DE69026986T2 (fr)
DK (2) DK0408284T3 (fr)
ES (1) ES2088971T3 (fr)
GB (1) GB8915712D0 (fr)
GR (1) GR3020680T3 (fr)
IE (1) IE62625B1 (fr)
SG (1) SG46382A1 (fr)
WO (1) WO1991000710A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2108122T3 (es) * 1991-05-24 1997-12-16 Amylin Pharmaceuticals Inc Composicion a base de amilina o de un analogo de amilina conteniendo opcionalmente insulina, para el tratamiento de la anorexia y de las patologias asociadas.
JPH06510753A (ja) * 1991-05-24 1994-12-01 アミリン・ファーマシューティカルズ，インコーポレイテッド インスリン欠乏哺乳動物治療用のインスリンおよびアミリンを含有する組成物
US5858684A (en) * 1991-08-23 1999-01-12 The Brigham And Women's Hospital, Inc. Method of screening calcium receptor-active molecules
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
WO1993019774A1 (fr) * 1992-04-03 1993-10-14 Amylin Pharmaceuticals, Inc. Composition contenant de l'amyline et eventuellement de l'insuline pour le traitement de l'anorexie et de maladies apparentees
US5962314A (en) * 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
EP1275635A1 (fr) 1994-10-21 2003-01-15 Nps Pharmaceuticals, Inc. Composés capables de moduler l'activité du récepteur de calcium
JP4117506B2 (ja) * 1996-05-01 2008-07-16 エヌピーエス ファーマシューティカルズ インコーポレイテッド 無機イオン活性化合物
AU9369098A (en) 1997-09-26 1999-04-23 Auckland Uniservices Limited Therapeutic method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925833A (en) * 1983-12-29 1990-05-15 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
GB8407907D0 (en) * 1984-03-27 1984-05-02 Sandoz Ltd Organic compounds
US4588716A (en) * 1984-05-04 1986-05-13 Wisconsin Alumni Research Foundation Method for treating metabolic bone disease in mammals
JPS62129297A (ja) * 1985-08-09 1987-06-11 Toyo Jozo Co Ltd カルシトニン遺伝子関連ペプチド誘導体
US4677132A (en) * 1986-03-12 1987-06-30 American Home Products Corporation Inhibition of bone resorption by etodolac
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
HU203198B (en) * 1987-10-26 1991-06-28 Sandoz Ag Process for producing pharmaceutical compositions having immunity-inhibiting, monokin-, particularly interleukin-1-inhibiting effect
WO1990000884A1 (fr) * 1988-07-22 1990-02-08 Ethyl Corporation Composes de silicium pour le traitement des os

Also Published As

Publication number Publication date
IE62625B1 (en) 1995-02-22
DK40191A (da) 1991-03-07
IE902494A1 (en) 1991-02-13
GR3020680T3 (en) 1996-10-31
CA2020752C (fr) 1996-12-24
DK40191D0 (da) 1991-03-07
JPH04500691A (ja) 1992-02-06
ATE137975T1 (de) 1996-06-15
DK0408284T3 (da) 1996-06-03
DE69026986D1 (de) 1996-06-20
EP0408284A3 (en) 1992-01-08
ES2088971T3 (es) 1996-10-01
EP0408284B1 (fr) 1996-05-15
GB8915712D0 (en) 1989-08-31
WO1991000710A1 (fr) 1991-01-24
DE69026986T2 (de) 1996-10-02
SG46382A1 (en) 1998-02-20
EP0408284A2 (fr) 1991-01-16

Similar Documents

Publication Publication Date Title
EP0408284A3 (en) Amylin for treatment of bone disorders
EP0309100A3 (fr) Emploi de l'amyline ou CGRP pour le traitement du diabète sucré
CS949087A2 (en) Stabilizer for thigh-bone's collum and upper end fracture treatment
PL341112A1 (en) Methods of providing postmenopausal treatment to female patients using very low doses of oestrogen
CA2011751A1 (fr) Plaque de fixation
AU3173297A (en) Exendin analogues, processes for their preparation and medicaments containing them
AU1808488A (en) Compounds for the treatment of alzheimer's disease
GB8618651D0 (en) Colles fracture brace
AU7793887A (en) Therapeutic composition comprising gamma-linolenic acid and calcium
IL88080A0 (en) Substituted tetralins,chromans and related compounds in the treatment of asthma,arthritis and related diseases
PT84662A (en) Process for the preparation of pharmaceutical compositions containing 7,alpha-]1(s)-hydroxy-1-methylbuthyl"-6,14-endoetheno-6,7,8,14-tetrahydro-oripavine (etorphine)
JPS6471889A (en) Novel 6-acyl-(6h)-dibenzo(c,e)(1,2)oxaphosphorine- 6-oxide, manufacture and use as photoinitiator
AU7142291A (en) Mechanism for mutual transformation of reciprocating and rotary motions
MY103790A (en) Novel compound for the treatment of several bone affecting diseases
EP0330756A3 (en) Thienotricyclics for the treatment of bronchial diseases
EP0486584A4 (en) Dopaminergic neurotrophic factor for treatment of parkinson's disease
EP0295827A3 (fr) Emploi de 24,25-dihydroxycholécalciférol pendant le processus de guérison de fractures d'os
GB8903565D0 (en) Bone cements
EP0301546A3 (fr) Emploi de l'étiocholanedione et compositions le contenant
NZ221473A (en) Octapeptide somatostatin analogue "octreotide" in nasal compositions
MY103584A (en) 8(alpha)-acylaminoergoline, its preparation and pharmaceutical compositions containing it
EP0173527A3 (fr) Analogues de la somatostatine insuline-sélective
Ashizuka Mechanical Properties of Phosphate Glasses and Ceramics
Yokoyama et al. Prognosis of Fracture of the Neck of the Femur
CS768788A1 (en) Dispersing agent for leathers' surface treatment properties improvement

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry